Activity of ceftaroline against extracellular (broth) and intracellular (THP-1 monocytes) forms of methicillin-resistant Staphylococcus aureus: Comparison with vancomycin, linezolid and daptomycin

Journal of Antimicrobial Chemotherapy

Volumn 68, Issue 3, 2013, Pages 648-658

  Mélard, Aurélie ^a   Garcia, Laetitia G ^a   Das, Debaditya ^a   Rozenberg, Raoul ^a   Tulkens, Paul M ^a   Van Bambeke, Françoise ^a   Lemaire, Sandrine ^a  

^a UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

Author keywords

Cfr; Hill equation; Linezolid resistant; Mass spectrometry; Maximal relative efficacy; Recursive partitioning analysis; Static concentration; VISA

Indexed keywords

CEFTAROLINE; DAPTOMYCIN; LINEZOLID; VANCOMYCIN;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL GROWTH; BACTERIAL STRAIN; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG POTENCY; DRUG STABILITY; GROWTH INHIBITION; IN VITRO STUDY; MASS SPECTROMETRY; MAXIMUM PLASMA CONCENTRATION; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; MONOCYTE; NONHUMAN; PHAGOCYTOSIS;

ACETAMIDES; ANTI-BACTERIAL AGENTS; CEPHALOSPORINS; DAPTOMYCIN; HUMANS; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MICROBIAL SENSITIVITY TESTS; MONOCYTES; OXAZOLIDINONES; VANCOMYCIN;

EID: 84873575424     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dks442     Document Type: Article

References (60)

1. Biek D, Critchley IA, Riccobene TA et al. Ceftaroline fosamil: a novel broad-spectrum cephalosporin with expanded anti-Gram-positive activity. J Antimicrob Chemother 2010; 65 Suppl 4: iv9-16.
2. Iizawa Y, Nagai J, Ishikawa T et al. In vitro antimicrobial activity of T-91825, a novel anti-MRSA cephalosporin, and in vivo anti-MRSA activity of its prodrug, TAK-599. J Infect Chemother 2004; 10: 146-56.
3. Flamm RK, Sader HS, Farrell DJ et al. Summary of ceftaroline activity against pathogens in the United States, 2010: Report from the Assessing Worldwide Antimicrobial Resistance Evaluation (AWARE) Surveillance Program. Antimicrob Agents Chemother 2012; 56: 2933-40.
4. Zhanel GG, Rossnagel E, Nichol K et al. Ceftaroline pharmacodynamic activity versus community-associated and healthcare-associated methicillin-resistant Staphylococcus aureus, heteroresistant vancomycinintermediate S. aureus, vancomycin-intermediate S. aureus and vancomycin-resistant S. aureus using an in vitro model. J Antimicrob Chemother 2011; 66: 1301-5.
5. Ishikawa T, Matsunaga N, Tawada H et al. TAK-599, a novel N-phosphono type prodrug of anti-MRSA cephalosporin T-91825: synthesis, physicochemical and pharmacological properties. Bioorg Med Chem 2003; 11: 2427-37.
6. Corrado ML. Integrated safety summary of CANVAS 1 and 2 trials: Phase III, randomized, double-blind studies evaluating ceftaroline fosamil for the treatment of patients with complicated skin and skin structure infections. J Antimicrob Chemother 2010; 65 Suppl 4: iv67-71.
7. Wilcox MH, Corey GR, Talbot GH et al. CANVAS 2: the second Phase III, randomized, double-blind study evaluating ceftaroline fosamil for the treatment of patients with complicated skin and skin structure infections. J Antimicrob Chemother 2010; 65 Suppl 4: iv53-65.
8. Corey GR, Wilcox MH, Talbot GH et al. CANVAS 1: the first Phase III, randomized, double-blind study evaluating ceftaroline fosamil for the treatment of patients with complicated skin and skin structure infections. J Antimicrob Chemother 2010; 65 Suppl 4: iv41-51.
9. Anonymous. TEFLARO Prescribing Information. Forest Pharmaceuticals, Inc., subsidiary of Forest Laboratories, Inc., St Louis, MO, USA. http://www. frx.com/pi/Teflaro_pi.pdf (11 October 2012, date last accessed). 9a Anonymous. ZINFORO Summary of Product Characteristics. European Medicines Agency, London, UK. http://www.ema.europa.eu/ (26 October 2012, date last accessed).
10. Friedland HD, O'Neal T, Biek D et al. CANVAS 1 and 2: analysis of clinical response at day 3 in two Phase 3 trials of ceftaroline fosamil versus vancomycin plus aztreonam in treatment of acute bacterial skin and skin structure infections. Antimicrob Agents Chemother 2012; 56: 2231-6.
11. Lowy FD. Is Staphylococcus aureus an intracellular pathogen? Trends Microbiol 2000; 8: 341-3.
12. Garzoni C, Kelley WL. Staphylococcus aureus: new evidence for intracellular persistence. Trends Microbiol 2009; 17: 59-65.
13. Van Bambeke F, Barcia-Macay M, Lemaire S et al. Cellular pharmacodynamics and pharmacokinetics of antibiotics: current views and perspectives. Curr Opin Drug Discov Devel 2006; 9: 218-30.
14. Sandberg A, Lemaire S, Van Bambeke F et al. Intra- and extracellular activities of dicloxacillin and linezolid against a clinical Staphylococcus aureus strain with a small-colony-variant phenotype in an in vitro model of THP-1 macrophages and an in vivo mouse peritonitis model. Antimicrob Agents Chemother 2011; 55: 1443-52.
15. Barcia-Macay M, Seral C, Mingeot-Leclercq MP et al. Pharmacodynamic evaluation of the intracellular activities of antibiotics against Staphylococcus aureus in a model of THP-1 macrophages. Antimicrob Agents Chemother 2006; 50: 841-51.
16. Lemaire S, Van Bambeke F, Mingeot-Leclercq MP et al. Activity of three b-lactams (ertapenem, meropenem and ampicillin) against intraphagocytic Listeria monocytogenes and Staphylococcus aureus. J Antimicrob Chemother 2005; 55: 897-904.
17. Page MG. Emerging cephalosporins. Expert Opin Emerg Drugs 2007; 12: 511-24.
18. Lemaire S, Glupczynski Y, Duval V et al. Activities of ceftobiprole and other cephalosporins against extracellular and intracellular (THP-1 macrophages and keratinocytes) forms of methicillin-susceptible and methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 2009; 53: 2289-97.
19. Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing: Twentieth Informational Supplement M100-S20. CLSI, Wayne, PA, USA, 2010.
20. Ohkuma S, Poole B. Fluorescence probe measurement of the intralysosomal pH in living cells and the perturbation of pH by various agents. Proc Natl Acad Sci USA 1978; 75: 3327-31.
21. Lemaire S, Van Bambeke F, Mingeot-Leclercq MP et al. Role of acidic pH in the susceptibility of intraphagocytic methicillin-resistant Staphylococcus aureus strains to meropenem and cloxacillin. Antimicrob Agents Chemother 2007; 51: 1627-32.
22. Tsuchiya S, Yamabe M, Yamaguchi Y et al. Establishment and characterization of a human acute monocytic leukemia cell line (THP-1). Int J Cancer 1980; 26: 171-6.
23. Carryn S, Van d V, Van Bambeke F et al. Impairment of growth of Listeria monocytogenes in THP-1 macrophages by granulocyte macrophage colony-stimulating factor: release of tumor necrosis factor-a and nitric oxide. J Infect Dis 2004; 189: 2101-9.
24. Lowry OH, Rosebrough NJ, Farr AL et al. Protein measurement with the Folin phenol reagent. J Biol Chem 1951; 193: 265-75.
25. Livermore DM. Has the era of untreatable infections arrived? J Antimicrob Chemother 2009; 64 Suppl 1: i29-36.
26. Bush K, Courvalin P, Dantas G et al. Tackling antibiotic resistance. Nat Rev Microbiol 2011; 9: 894-6.
27. Arias CA, Mendes RE, Stilwell MG et al. Unmet needs and prospects for oritavancin in the management of vancomycin-resistant enterococcal infections. Clin Infect Dis 2012; 54 Suppl 3: S233-8.
28. Sincak CA, Schmidt JM. Iclaprim, a novel diaminopyrimidine for the treatment of resistant gram-positive infections. Ann Pharmacother 2009; 43: 1107-14.
29. Bush K, Heep M, Macielag MJ et al. Anti-MRSA b-lactams in development, with a focus on ceftobiprole: the first anti-MRSA b-lactam to demonstrate clinical efficacy. Expert Opin Investig Drugs 2007; 16: 419-29.
30. Rubinstein E, Prokocimer P, Talbot GH. Safety and tolerability of quinupristin/dalfopristin: administration guidelines. J Antimicrob Chemother 1999; 44 Suppl A: 37-46.
31. Falagas ME, Karageorgopoulos DE, Dimopoulos G. Clinical significance of the pharmacokinetic and pharmacodynamic characteristics of tigecycline. Curr Drug Metab 2009; 10: 13-21.
32. Di Paolo A, Malacarne P, Guidotti E et al. Pharmacological issues of linezolid: an updated critical review. Clin Pharmacokinet 2010; 49: 439-47.
33. Smith WJ, Drew RH. Telavancin: a new lipoglycopeptide for grampositive infections. Drugs Today (Barc) 2009; 45: 159-73.
34. Seaton RA. Daptomycin: rationale and role in the management of skin and soft tissue infections. J Antimicrob Chemother 2008; 62 Suppl 3: iii15-23.
35. Sakoulas G, Moise-Broder PA, Schentag J et al. Relationship of MIC and bactericidal activity to efficacy of vancomycin for treatment of methicillin-resistant Staphylococcus aureus bacteremia. J Clin Microbiol 2004; 42: 2398-402.
36. Haque NZ, Zuniga LC, Peyrani P et al. Relationship of vancomycin minimum inhibitory concentration to mortality in patients with methicillinresistant Staphylococcus aureus hospital-acquired, ventilator-associated, or health-care-associated pneumonia. Chest 2010; 138: 1356-62.
37. Ikeda-Dantsuji Y, Hanaki H, Sakai F et al. Linezolid-resistant Staphylococcus aureus isolated from 2006 through 2008 at six hospitals in Japan. J Infect Chemother 2011; 17: 45-51.
38. Witte W, Cuny C. Emergence and spread of cfr-mediated multiresistance in staphylococci: an interdisciplinary challenge. Future Microbiol 2011; 6: 925-31.
39. Moisan H, Pruneau M, Malouin F. Binding of ceftaroline to penicillinbinding proteins of Staphylococcus aureus and Streptococcus pneumoniae. J Antimicrob Chemother 2010; 65: 713-6.
40. Kosowska-Shick K, McGhee PL, Appelbaum PC. Affinity of ceftaroline and other b-lactams for penicillin-binding proteins from Staphylococcus aureus and Streptococcus pneumoniae. Antimicrob Agents Chemother 2010; 54: 1670-7.
41. Villegas-Estrada A, Lee M, Hesek D et al. Co-opting the cell wall in fighting methicillin-resistant Staphylococcus aureus: potent inhibition of PBP 2a by two anti-MRSA b-lactam antibiotics. J Am Chem Soc 2008; 130: 9212-3.
42. Vidaillac C, Leonard SN, Rybak MJ. In vitro activity of ceftaroline against methicillin-resistant Staphylococcus aureus and heterogeneous vancomycin-intermediate S. aureus in a hollow fiber model. Antimicrob Agents Chemother 2009; 53: 4712-7.
43. Stratton CW, Liu C, Weeks LS. Activity of LY146032 compared with that of methicillin, cefazolin, cefamandole, cefuroxime, ciprofloxacin, and vancomycin against staphylococci as determined by kill-kinetic studies. Antimicrob Agents Chemother 1987; 31: 1210-5.
44. Seral C, Van Bambeke F, Tulkens PM. Quantitative analysis of gentamicin, azithromycin, telithromycin, ciprofloxacin, moxifloxacin, and oritavancin (LY333328) activities against intracellular Staphylococcus aureus in mouse J774 macrophages. Antimicrob Agents Chemother 2003; 47: 2283-92.
45. Barcia-Macay M, Lemaire S, Mingeot-Leclercq MP et al. Evaluation of the extracellular and intracellular activities (human THP-1 macrophages) of telavancin versus vancomycin against methicillinsusceptible, methicillin-resistant, vancomycin-intermediate and vancomycin-resistant Staphylococcus aureus. J Antimicrob Chemother 2006; 58: 1177-84.
46. Baudoux P, Lemaire S, Denis O et al. Activity of quinupristin/ dalfopristin against extracellular and intracellular Staphylococcus aureus with various resistance phenotypes. J Antimicrob Chemother 2010; 65: 1228-36.
47. Lemaire S, Kosowska-Shick K, Appelbaum PC et al. Activity of moxifloxacin against intracellular community-acquired methicillinresistant Staphylococcus aureus: comparison with clindamycin, linezolid and co-trimoxazole and attempt at defining an intracellular susceptibility breakpoint. J Antimicrob Chemother 2011; 66: 596-607.
48. Vallet CM, Marquez B, Ngabirano E et al. Cellular accumulation of fluoroquinolones is not predictive of their intracellular activity: studies with gemifloxacin, moxifloxacin and ciprofloxacin in a pharmacokinetic/ pharmacodynamic model of uninfected and infected macrophages. Int J Antimicrob Agents 2011; 38: 249-56.
49. Lemaire S, Van Bambeke F, Tulkens PM. Cellular accumulation and pharmacodynamic evaluation of the intracellular activity of CEM-101, a novel fluoroketolide, against Staphylococcus aureus, Listeria monocytogenes, and Legionella pneumophila in human THP-1 macrophages. Antimicrob Agents Chemother 2009; 53: 3734-43.
50. Lemaire S, Van Bambeke F, Appelbaum PC et al. Cellular pharmacokinetics and intracellular activity of torezolid (TR-700): studies with human macrophage (THP-1) and endothelial (HUVEC) cell lines. J Antimicrob Chemother 2009; 64: 1035-43.
51. Mushtaq S, Warner M, Ge Y et al. In vitro activity of ceftaroline (PPI-0903M, T-91825) against bacteria with defined resistance mechanisms and phenotypes. J Antimicrob Chemother 2007; 60: 300-11.
52. Clark C, McGhee P, Appelbaum PC et al. Multistep resistance development studies of ceftaroline in gram-positive and -negative bacteria. Antimicrob Agents Chemother 2011; 55: 2344-51.
53. Chan L, Chambers H. MecA-independent high-level b-lactam resistance in Staphylococcus aureus strains passaged in ceftobiprole and ceftaroline. In: Abstracts of the Fifty-second Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA, USA, 2012. Abstract C1-1351a, p. 300. American Society for Microbiology, Washington, DC, USA.
54. Baudoux P, Bles N, Lemaire S et al. Combined effect of pH and concentration on the activities of gentamicin and oxacillin against Staphylococcus aureus in pharmacodynamic models of extracellular and intracellular infections. J Antimicrob Chemother 2007; 59: 246-53.
55. Lemaire S, Fuda C, Van Bambeke F et al. Restoration of susceptibility of methicillin-resistant Staphylococcus aureus to b-lactam antibiotics by acidic pH: role of penicillin-binding protein PBP 2a. J Biol Chem 2008; 283: 12769-76.
56. Marconescu P, Graviss EA, Musher DM. Rates of killing of methicillinresistant Staphylococcus aureus by ceftaroline, daptomycin, and telavancin compared to that of vancomycin. Scand J Infect Dis 2012; 44: 620-2.
57. Graves SF, Kobayashi SD, Braughton KR et al. Relative contribution of Panton-Valentine leukocidin to PMN plasma membrane permeability and lysis caused by USA300 and USA400 culture supernatants. Microbes Infect 2010; 12: 446-56.
58. Tong A, Tong SY, Zhang Y et al. Panton-Valentine leukocidin is not the primary determinant of outcome for Staphylococcus aureus skin infections: evaluation from the CANVAS studies. PLoS One 2012; 7: e37212.
59. Mouton JW, Brown DF, Apfalter P et al. The role of pharmacokinetics/ pharmacodynamics in setting clinical MIC breakpoints: the EUCAST approach. Clin Microbiol Infect 2012; 18: E37-45.
60. Stratton CW, Weeks LS. Effect of human serum on the bactericidal activity of daptomycin and vancomycin against staphylococcal and enterococcal isolates as determined by time-kill kinetic studies. Diagn Microbiol Infect Dis 1990; 13: 245-52.